NCT07463300 A Hierarchical Multi-modal AI Framework for Pathological and Genetic Subtyping of Lung Cancer Based on PET/CT Imaging
| NCT ID | NCT07463300 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Condition | Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,500 participants |
| Start Date | 2024-08-01 |
| Primary Completion | 2027-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,500 participants in total. It began in 2024-08-01 with a primary completion date of 2027-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
PET/CT imaging and clinical information (age, gender, smoking history, family history of cancer, history of present illness, and several tumor biomarkers, etc.) were used to establish a hierarchical multi-modal AI framework for pathological and genetic subtyping of lung cancer
Eligibility Criteria
Inclusion Criteria: * Newly diagnosed NSCLC confirmed pathologically * Age ≥18 y * Underwent pre-treatment 18F-FDG PET/CT scan * No prior anti-tumor treatments * No history of other malignancies Exclusion Criteria: ▪ Pure ground-glass nodules with no FDG uptake
Contact & Investigator
Hong Zhang
PRINCIPAL INVESTIGATOR
Department of Nuclear Medicine and PET/CT Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University
Frequently Asked Questions
Who can join the NCT07463300 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07463300 currently recruiting?
Yes, NCT07463300 is actively recruiting participants. Contact the research team at hzhang21@zju.edu.cn for enrollment information.
Where is the NCT07463300 trial being conducted?
This trial is being conducted at Guangzhou, China, Wuhan, China, Wuhan, China, Yangzhou, China and 5 additional locations.
Who is sponsoring the NCT07463300 clinical trial?
NCT07463300 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. The principal investigator is Hong Zhang at Department of Nuclear Medicine and PET/CT Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University. The trial plans to enroll 5,500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.